ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Bioenvision Ltd Withdraws Its Application For An Extension Of Indication For Evoltra (clofarabine) - Europe
The European Medicines Agency (EMEA) has been formally notified by Bioenvision Ltd, a wholly
owned subsidiary of Genzyme Corporation, of its decision to withdraw its application for an extension
of indication for the centrally authorised medicine Evoltra (clofarabine).
Evoltra was expected to be used for the treatment of acute myeloid leukaemia in elderly patients.
Evoltra was first authorised in the European Union on 29 May 2006. It is currently indicated for the
treatment of acute lymphoblastic leukaemia in paediatric patients.
The application for the extension of indication for Evoltra was submitted to the EMEA on 7 February
2007. In its official letter, the company stated that the withdrawal of the application was based on the
CHMP's opinion that the data provided did not allow the Committee to conclude that the benefits of
the medicine outweigh the risks. However, data could be provided in order to support a resubmission
in this indication in the near future.
More information about Evoltra and the state of the scientific assessment at the time of the withdrawal
will be made available in a question-and-answer document. This document, together with the
withdrawal letter from the company, will be published on the EMEA website in due course.
Withdrawal of an application does not prejudice the possibility of a company making a new
application at a later stage.
European Medicines Agency
Bioenvision Ltd retrage cererea de prelungire de indicaþie Pentru Evoltra (clofarabine) - Europa - Bioenvision Ltd Withdraws Its Application For An Extension Of Indication For Evoltra (clofarabine) - Europe - articole medicale engleza - startsanatate